Cancer drugs and the heart: importance and management
Top Cited Papers
Open Access
- 12 July 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (15), 1102-1111
- https://doi.org/10.1093/eurheartj/ehs181
Abstract
Progress in the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. Due to their mechanism of action, however, conventional chemotherapeutics and some of the newer anti-cancer signaling inhibitors carry a substantial risk of cardiovascular side effects that include cardiac dysfunction and heart failure, arterial hypertension, vasospastic and thromboembolic ischaemia, dysrhythmia, and QT prolongation. While some of these side effects are irreversible and cause progressive cardiovascular disease, others induce only temporary dysfunction with no apparent long-term sequelae for the patient. The challenge for the cardiovascular specialist is to balance the need for life-saving cancer treatment with the assessment of risk from cancer drug-associated cardiovascular side effects to prevent long-term damage. This review discusses concepts for timely diagnosis, intervention, and surveillance of cancer patients undergoing treatment, and provides approaches to clinical uncertainties.Keywords
This publication has 66 references indexed in Scilit:
- A Historical Perspective of Anthracycline CardiotoxicityHeart Failure Clinics, 2011
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsBMC Cancer, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal Of Cancer, 2010
- Cardiovascular Complications of Cancer Therapy: Incidence, Pathogenesis, Diagnosis, and ManagementJournal of the American College of Cardiology, 2009
- Anthracycline Cardiotoxicity: From Bench to BedsideJournal of Clinical Oncology, 2008
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Mechanisms and Models in Heart FailureCirculation, 2005
- Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapyAnnals of Oncology, 2002
- Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2Circulation, 2002
- A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.Journal of Clinical Oncology, 1984